Courier Capital LLC boosted its holdings in shares of Celgene Corporation (NASDAQ:CELG) by 1.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,987 shares of the biopharmaceutical company’s stock after purchasing an additional 38 shares during the quarter. Courier Capital LLC’s holdings in Celgene Corporation were worth $258,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of CELG. Toronto Dominion Bank increased its holdings in Celgene Corporation by 22.6% during the 1st quarter. Toronto Dominion Bank now owns 413,342 shares of the biopharmaceutical company’s stock worth $51,426,000 after purchasing an additional 76,322 shares during the last quarter. Eagle Asset Management Inc. increased its holdings in Celgene Corporation by 1.5% during the 1st quarter. Eagle Asset Management Inc. now owns 20,128 shares of the biopharmaceutical company’s stock worth $2,504,000 after purchasing an additional 295 shares during the last quarter. Warren Averett Asset Management LLC purchased a new stake in Celgene Corporation during the 1st quarter worth approximately $438,000. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in Celgene Corporation during the 1st quarter worth approximately $118,000. Finally, Sawtooth Solutions LLC increased its holdings in Celgene Corporation by 19.8% during the 1st quarter. Sawtooth Solutions LLC now owns 8,307 shares of the biopharmaceutical company’s stock worth $1,034,000 after purchasing an additional 1,375 shares during the last quarter. Institutional investors own 79.48% of the company’s stock.
CELG has been the topic of several analyst reports. Vetr downgraded Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective on the stock. in a report on Tuesday, August 29th. Royal Bank Of Canada lowered their price target on Celgene Corporation from $166.00 to $148.00 and set a “top pick” rating for the company in a report on Friday, October 27th. Leerink Swann reiterated a “buy” rating and issued a $156.00 price target on shares of Celgene Corporation in a report on Friday, October 20th. Morgan Stanley lowered their price target on Celgene Corporation from $120.00 to $115.00 and set an “underweight” rating for the company in a report on Monday, October 23rd. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Celgene Corporation in a report on Monday, August 28th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $139.87.
Shares of Celgene Corporation (CELG) opened at $104.10 on Monday. Celgene Corporation has a fifty-two week low of $94.55 and a fifty-two week high of $147.17. The company has a market capitalization of $81,959.70, a price-to-earnings ratio of 16.27, a PEG ratio of 0.80 and a beta of 1.79. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.
Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the consensus estimate of $1.87 by $0.04. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The business had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the prior year, the business posted $1.58 earnings per share. Celgene Corporation’s revenue was up 10.2% compared to the same quarter last year. sell-side analysts anticipate that Celgene Corporation will post 6.67 EPS for the current year.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.